DF Medica was established in 2004 in Bergamo, Italy, as a company involved in the field of Life Sciences, conducting research on products related to health and wellness management. Since the sequencing of the entire human genome, DF Medica dedicated its activities to the research and development of products and solutions based on the analysis of the individual genetic makeup with predictive purposes, thus interpreting the growing interest of medical science for preventive medicine.
At first the backbone of DF Medica’s research was represented by the possibility to investigate the individual predisposition to common diseases, such as those related to the cardiovascular system and to the autonomic nervous system. However, all this lead to the development of what would become DF Medica’s primary interest.
It all began with the popular quote from Hippocrates (IV cent. B.C.) “Let food be thy medicine and medicine be thy food”. This ancient principle is ever true in the era of DNA sequencing. If food is the best medicine available, we need to know our body’s true needs and such investigation is only possible through genetic analysis.
Progress in scientific knowledge and technology is fundamental within this process. Moreover, the speed at which science and technology advance represent a constant stimulus for our future challenges.
On the one hand the constant update of high-impact international research studies provides the framework used by DF Medica’s Science Advisory Board to identify new analysis panels and build evaluation algorithms. On the other, advances in technology allow to analyze ever more complex panels and progressively approach the extraordinary complexity of the human body.
DF Medica is a company part of the Finlinea Group.